30 results about "Crohns diseases" patented technology

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and / or for the provision of an increased barrier function of the gutmucosa.

Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

The present disclosure provides methods for assessing mucosal healing in a patient with Chron's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

The invention relates to methods of administering beta7 integrin antagonists. Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohns disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.

A monoclonal antibody or an antigen-binding fragment thereof against Ig-like domain receptor 2 (ILDR2) is provided, the monoclonal antibody can specifically bind to ILDR2, and can effectively inhibit its ILDR2 immune function, and the present invention also provides Provides a pharmaceutical composition comprising the monoclonal antibody and its use, the pharmaceutical composition has the ability to prepare and assist in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, and systemic sclerosis , systemic lupus erythematosus, Crohn's disease, drug potential for allergic asthma.

The invention discloses the application of an antibacterial peptide in the preparation of a medicine for regulating intestinal flora, and the antibacterial peptide is RNASE4. The antimicrobial peptide significantly increased the proportion of Akkermansia bacteria in the intestinal tract, while the proportion of Spirulina mucilage significantly decreased in the intestinal tract. The invention also discloses the application of the antibacterial peptide in the preparation of medicine for treating inflammatory bowel disease. The antibacterial peptide is RNASE4; the inflammatory bowel disease includes ulcerative colitis and Crohn's disease.

The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintainance of a healthy gut-mucosa and / or for the provision of an increased barrier function of the gut-mucosa.

The present application provides compositions, eg, formulations, for gastric, gastrointestinal and / or colonic therapy; and methods for making, storing and using them, including storage at ambient temperature, including long-term storage. The compositions provided herein are useful in the treatment of various diseases or conditions, such as autism spectrum disorder, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.

The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and / or for the provision of an increased barrier function of the gut-mucosa.

The invention relates to the field of biomedicine, in particular to the application of Lichang Decoction in the preparation of medicines for treating Crohn's disease. The technical solution provided by the invention can significantly improve the occult blood, blood in the stool, weight loss, DAI score, pathological changes and other diseases caused by Crohn's disease (CD), and opens up a new application for Lichang Decoction.

The invention relates to the technical field of biological printing, in particular to a replaceable 3D printing nozzle for Crohn disease perianal fistula, which comprises a nozzle main body, a partition plate fixing block is arranged at the upper part in the nozzle main body, an air guide inner diameter is formed in the partition plate fixing block, a locking plate pipe diameter connecting part is arranged on one side of the air guide inner diameter, and a locking plate pipe diameter connecting part is arranged on the other side of the locking plate pipe diameter connecting part. And a clamping ball pipe diameter connecting part is arranged below the locking plate pipe diameter connecting part. According to the replaceable 3D printing nozzle for the crissum fistula of the Crohn disease, a clamping ball structure and a locking plate structure are linked through a clamping ball pipe diameter connecting part, an air guide inner diameter and a locking plate pipe diameter connecting part, so that automatic locking of the 3D printing nozzle is completed; the situation that normal use of a biological 3D printer is affected by a 3D printing nozzle gyroscope due to unstable installation in the use process of the 3D printing nozzle is avoided, after use is finished, the 3D printing nozzle can be disassembled and unlocked only by disassembling the air discharging cover and releasing air in the air guiding inner diameter, and the 3D printing nozzle is convenient to assemble and disassemble.

A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and / or by said vector.